Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection-Reference-Cited by-同舟云学术

Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection

Published:2020-07-12 Issue:6 Volume:13 Page:1233-1238
ISSN:1865-7257
Container-title:Clinical Journal of Gastroenterology
language:en
Short-container-title:Clin J Gastroenterol

Author:

Takaki Shintaro,Imamura Michio^ORCID,Yamaguchi Shuji,Fukuhara Takayuki,Mori Nami,Tsuji Keiji,Ohya Kazuki,Hayes Clair Nelson,Aikata Hiroshi,Chayama Kazuaki

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12328-020-01182-9.pdf

Reference29 articles.

1. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.

2. Uchida Y, Kouyama JI, Naiki K, et al. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. Hepatol Res. 2016;46:1234–46.

3. Itakura J, Kurosaki M, Higuchi M, et al. Resistance-associated NS5A variants of hepatitis C virus are susceptible to interferon-based therapy. PLoS ONE. 2015;10:e0138060.

4. Teraoka Y, Uchida T, Imamura M, et al. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Biochem Biophys Res Commun. 2018;500:152–7.

5. Hikita H, Takehara T. NS5A-P32 deletion in hepatitis C genotype 1b infection is the most refractory treatment-mediated amino acid change exhibiting resistance to all NS5A inhibitors. Semin Liver Dis. 2019. https://doi.org/10.1055/s-0039-3402001(Epub ahead of print).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed;Internal Medicine;2021-11-01

2. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral;Global Health & Medicine;2021-10-31

3. Treatment failure with DAA therapy: Importance of resistance;Journal of Hepatology;2021-06